EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the ...
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.685
https://www.valueinhealthjournal.com/article/S1098-3015(22)00886-5/fulltext
Title :
EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00886-5&doi=10.1016/j.jval.2022.04.685
First page :
Section Title :
Open access? :
No
Section Order :
10615